From AI love affairs to cosmic survival, 2026 has it all.
Updated
January 8, 2026 6:28 PM
A man in a space suit looking upon a ringed marble. PHOTO: UNSPLASH
Grab your popcorn—the 2026 sci-fi movie slate is stacked. We’re getting everything from post-apocalyptic survival films to AI thrillers, plus a big-space adventure and a fresh DC superhero story. Some films launch new worlds, others expand familiar ones, but all of them aim to leave an impression, but all of them look like the kind of movies you’ll want to talk about after the credits.
Here are five upcoming sci-fi movies to mark on your calendar.
Release Date: January 9, 2026
Director: Kate Dolan
Stars: Lily Sullivan, David Rysdahl and Claudia Doumit
If you like your sci-fi with a creepy edge, Soulm8te is very much in that lane. A spin-off from the M3GAN universe, the film follows a man grieving the loss of his wife who turns to an AI android to ease the pain. At first, it seems to help. The connection feels real, even comforting. But before long, it becomes a little too real and slips into something far more dangerous. What makes Soulm8te unsettling is how close it feels to the present. AI companions are no longer science fiction, and the film plays with that reality in a way that feels intimate rather than futuristic. Directed by Kate Dolan, the story stays on quiet unease instead of spectacle, allowing tension to build as affection turns possessive and attachment becomes dangerous. The film is produced by Allison Williams and James Wan, both closely involved in the hit horror franchise M3GAN, and their experience with technology-driven horror is clearly felt here. Fans of grounded, psychological sci-fi should keep this one on their radar.
Release Date: January 9, 2026
Director: Ric Roman Waugh
Stars: Gerard Butler, Morena Baccarin, Amber Rose Revah, Sophie Thompson, Trond Fausa Aurvåg
Back in 2020, Greenland introduced audiences to John Garrity (Gerard Butler), a father racing against time to save his family as comet fragments threatened to wipe out life on Earth. The film ended with survivors heading into bunkers deep in Greenland, hanging on to the last thin thread of hope. This sequel follows the Garrity family as they leave the safety of underground shelters and face a world that no longer resembles home. The setting moves across a battered Europe, where every decision carries weight and every journey feels uncertain. Rather than repeating the ticking-clock chaos of the original, Migration leans into endurance, exhaustion and the question of whether rebuilding is even possible. It’s a post-apocalyptic movie about movement, loss and the cost of starting over.
Release Date: March 20, 2026
Director: Phil Lord & Chris Miller
Stars: Ryan Gosling, Milana Vayntrub, Sandra Hüller
Based on Andy Weir’s best-selling novel, Project Hail Mary is shaping up to be one of the most talked-about space survival films of 2026. Ryan Gosling stars as Ryland Grace, an unlikely astronaut whose journey into space begins with confusion rather than heroics. Grace, a former junior high science teacher, wakes up alone on a spacecraft, cut off from Earth and missing key memories about how he got there. As pieces slowly fall into place, so does the scale of the problem he’s been sent to solve. The film blends real science with high-stakes isolation, balancing quiet moments with the pressure of a mission that affects the entire planet. Directed by Phil Lord and Chris Miller, Project Hail Mary promises tension, curiosity and a heavy dose of human vulnerability set against the vastness of space.
Release Date: March 27, 2026
Director: Ridley Scott
Stars: Jacob Elordi, Josh Brolin
The Dog Stars strips the apocalypse down to its bare essentials. Based on Peter Heller’s novel of the same name, the film features a screenplay by Mark L. Smith and Christopher Wilkinson, known for The Revenant and Ali. The setup of The Dog Stars is simple and bleak: a virus has erased most of humanity. What’s left is silence, abandoned airfields and roaming scavengers known as the “Reapers” who prey on the few survivors left behind.
Jacob Elordi plays Hig, a pilot living in isolation with his dog and a heavily armed companion. His days follow a strict routine, broken only by short flights in his aging Cessna. That fragile balance shatters when a distant radio signal breaks through the quiet. It’s the first real sign of life he has heard in years, and it draws him toward a journey that could change everything. Directed by Ridley Scott, the film focuses less on large-scale destruction and more on loneliness, hope and the risk of reaching out in a broken world. The result is a post-apocalyptic thriller that feels intimate, reflective and quietly tense.
Release Date: June 26, 2026
Director: Craig Gillespie
Stars: Milly Alcock, Jason Momoa, Matthias Schoenaerts
Supergirl: Woman of Tomorrow offers a very different take on the DC universe. This is a cosmic sci-fi story first, superhero film second. Kara Zor-El is older, tougher and shaped by memories of a world she lost. Unlike her cousin Superman, she remembers the destruction of Krypton clearly, and that history weighs heavily on her. The film follows Kara as she crosses paths with a young alien seeking justice, pulling her into a dangerous journey across distant worlds. Rather than focusing on Earth-saving spectacle, the story explores identity, grief and what heroism looks like far from home. With Milly Alcock stepping into the role, Supergirl 2026 aims to expand DC’s sci-fi side while giving the character emotional depth rarely seen on screen.
One reason science fiction movies stick with us is that they ask big questions in a way that feels personal. What happens when tech starts filling emotional gaps? What does survival look like when the world doesn’t bounce back? And how far would you go to save everyone you’ve ever known? If you’re looking for 2026 sci-fi movies that range from gritty to hopeful to unsettling, this lineup has you covered.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.